 |  | | Investor Relations Home | Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem. | | |
|
| Date | Title | | | 07/07/10 | Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules| JERUSALEM, Israel, July 7, 2010 /PRNewswire via COMTEX/ --Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of
oral delivery systems, today announced that Oramed entered into a
Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the
MSA, sanofi-aventis will supply Oramed with specified quantities of
recombinant human insulin to be used by Oramed for its clinical trials in the
USA.
The MSA is managed by the Commercial and External Part... |
|  | | 06/28/10 | Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association| JERUSALEM, June 28, 2010 /PRNewswire via COMTEX/ --Results of First Exposure of Type I Diabetes Patients to Oramed's Oral
Insulin and of a First-in-Humans Study With its Oral GLP-1 Analog
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that its
executive management is participating in the 2010 Scientific Sessions of the
American Diabetes Association currently being held in Orlando, Florida. Dr.
Miriam Kidron, Chief Scientific Officer, is scheduled to present results of
two o... |
| | | 06/15/10 | Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010| JERUSALEM, June 15, 2010 /PRNewswire via COMTEX/ --Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of
alternative drug delivery systems, announced today that results of two of its
clinical trials will be presented by Chief Scientific Officer Dr. Miriam
Kidron, at the forthcoming 70th Annual Scientific Sessions of the American
Diabetes Association, to be held in Orlando, Florida. The first abstract,
entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Respo... |
| | | 06/08/10 | Oramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010| Oramed to Present on Wednesday, June 16th at 11:50 a.m. (IDT)
JERUSALEM, June 8, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB), (http://www.oramed.com), a developer of oral delivery
systems, today announced today that it was chosen to present at the 9th
National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010.
The presentation will be given by Nadav Kidron, Chief Executive Officer of
Oramed, on Wednesday, June 16th during the BioPharma... |
| | | 06/02/10 | Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.| JERUSALEM, June 2, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals
Inc. (OTCBB: ORMP), a developer of oral drug delivery systems, announced
today that its subsidiary Oramed Ltd. entered into a joint venture agreement
with Laser Detect Systems Ltd. ("Laser Detect"), an Israeli company listed on
the Tel Aviv Stock Exchange, for the establishment of a new company to be
called Entera Bio Ltd. ("Entera"). Under the terms of the agreement, Oramed
will out-license technology to Entera for t... |
| |
|
|
| | There are currently no events scheduled. |
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
|
|
